Anteo Diagnostics & Sona Nanotech team up to improve lateral flow tests
Category: #health  By Pankaj Singh  Date: 2019-01-17
  • share
  • Twitter
  • Facebook
  • LinkedIn

Anteo Diagnostics & Sona Nanotech team up to improve lateral flow tests

* The collaboration aims to help accelerate the development & enhance lateral flow immunoassays’ performance.

* Under the collaboration agreement, Sona’s gold nanorod tech would be merged with Anteo’s AnteoBind and several other biomarkers.

Anteo Diagnostics (Anteo), an Australian nanotechnology firm, has reportedly announced that it has signed a collaboration agreement with Canadian gold nanotechnology company, Sona Nanotech Inc. (Sona) to improve lateral flow tests’ performance.

Reports cite, the collaboration aims to help accelerate the development of lateral flow immunoassays, also called as lateral flow tests, while also attempting to enhance their performance.

According to a press release by Sona Nanotech, under the collaboration, Sona would be supplying its innovative gold nanorod technology to the Australian firm, which would be combining it with its own proprietary technology, AnteoBind™ as well as several other biomarkers such as sepsis (CRP), cardic (cTnI) markers & HCG, a renowned fertility marker utilized in home pregnancy tests.

Through the collaboration, both firms intend to develop a number of reagent sets that would greatly benefit developers of lateral flow immunoassays across the world, boost test performance, lessen the production process timeframes and promote multiplexing.

The Chief Executive Officer of Anteo Diagnostics, Christopher Parker stated that with this partnership, the company would be using crucial point of care (POC) targets in the segments of sepsis, cardiac and pregnancy testing in an effort to assess the enhancements that could be brought to the tests. Parker further added the positive results of the collaboration would encourage global lateral flow test developers to readily adopt the firms’ co-developed products.

For the record, Immunoassays are easy and relatively inexpensive to manufacture, in a market that is worth over $6 billion according to a 2018 estimate. Over two billion such tests are produced across the world on a yearly basis.

According to reports, the financial information related to the collaboration agreement has not been unveiled yet.



About Author

Pankaj Singh

Email: [email protected]   

Pankaj Singh

Pankaj Singh Develops content for Market Size Forecasters, Algosonline, and a couple of other platforms. A Post Graduate in Management by qualification, he worked as an underwriter in the UK insurance domain before deciding to switch his field of profession. With exp...

Read More

More News By Pankaj Singh

Novartis’ trial of Entresto reveals potential beyond HFrEF treatment
Novartis’ trial of Entresto reveals potential beyond HFrEF treatment
By Pankaj Singh

Swiss pharma-company Novartis has reportedly revealed subgroup results from its global PARAGON-HF Phase III study. The trial involved a study of patients suffering from HFpEF (heart failure with preserved ejection frac...

Nike to halt direct sale of its shoes and clothes through Amazon
Nike to halt direct sale of its shoes and clothes through Amazon
By Pankaj Singh

In efforts to retain their relevance in the continuously evolving world of ecommerce, companies are losing the personal touch they once had with their customers. Lately however, prominent brands that have a well-establ...

Stanford medicine releases its research on Apple Heart watches
Stanford medicine releases its research on Apple Heart watches
By Pankaj Singh

  • The study comprised enrollment of over 400,000 people, making it one of the biggest research efforts.
     
  • It also saw approximately 2,000...